EFFECTS OF ICOSAPENT ETHYL ON VASCULAR REGENERATIVE CELLS IN INDIVIDUALS WITH ELEVATED TRIGLYCERIDES: INSIGHTS FROM THE IPE-PREVENTION CARDIOLINK-14 TRIAL
Ehab Bakbak(The University of Queensland), Subodh Verma(St. Michael's Hospital), C. David Mazer(St. Michael's Hospital), Basel Bari(Custom Security Industries (Canada)), Hwee Teoh(St. Michael's Hospital), Aishwarya Krishnaraj(St. Michael's Hospital), Kristin Terenzi(Toronto Public Health), David A. Hess(Western University), Brady Park(St. Michael's Hospital), Daniella C. Terenzi(St. Michael's Hospital), Lawrence A. Leiter(St. Michael's Hospital), Adrian Quan(St. Michael's Hospital), Yi Pan(St. Michael's Hospital), Ori D. Rotstein(St. Michael's Hospital), Asaad I. Bakbak(Lakeridge Health), Deepak L. Bhatt(Mount Sinai Hospital)
Cited by 0
Related Papers
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
|New England Journal of Medicine|2019|6.8k
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
|New England Journal of Medicine|2018|6.3k
Empagliflozin in Heart Failure with a Preserved Ejection Fraction
|New England Journal of Medicine|2021|4.6k
Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome
|New England Journal of Medicine|2018|3.5k
Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia
|New England Journal of Medicine|2018|3.2k